Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis

Apathologically confirmed HLH case that presented with maculopapular skin lesions after certolizum-ab treatment is being reported in this presentation.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome that may betriggered by hereditary factors, autoimmune and immunologic disorders, infectious diseases, malig-nancies and medications.

📊

Key Findings & Data:Suspicion of the disease and early treatment is of paramount importance.Since the presentation of HLH with only skin involvement is rare, early diagnosis may be difficult.

💡

Conclusion & Impact:Apathologically confirmed HLH case that presented with maculopapular skin lesions after certolizum-ab treatment is being reported in this presentation.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome that may betriggered by hereditary factors, autoimmune and immunologic disorders, infectious diseases, malig-nancies and medications. Suspicion of the disease and early treatment is of paramount importance.Since the presentation of HLH with only skin involvement is rare, early diagnosis may be difficult. Apathologically confirmed HLH case that presented with maculopapular skin lesions after certolizum-ab treatment is being reported in this presentation.

🔖

Cite This Article

ALTINTAŞ, N. D., TALAN, L., HEPER, A., GÜVEN, G., GÜLER, A., TURGAY, T. M., ÖZYÜNCÜ, N. (2022). Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis. European Journal of Rheumatology, Cilt: 5 - Sayı: 3, 203–205. https://ajindex.com/articles/511681

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

George MR. Hemophagocytic lymphohistiocy- tosis: review of etiologies and management. J Blood Med 2014; 5: 69-86. [CrossRef ] Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis and rheumatism 2003; 49: 633-9. [CrossRef ] Henter JI, Horne A, Arico M, Egeler RM, Filipov- ich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocyt- ic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-31. [CrossRef ] Glaspole I, Hoy R, Ryan P. Comment on: A case of certolizumab-induced interstitial lung dis- ease in a patient with rheumatoid arthritis: reply. Rheumatology (Oxford) 2014; 53: 1155. [CrossRef ] Biedermann L, Kerl K, Rogler G, Hofbauer GF. Drug-induced erythema nodosum after the ad- ministration of certolizumab in Crohn’s disease. Inflamm Bowel Dis 2013; 19: E4-6. [CrossRef ] Oda Y, Urushidani Y, Ooi S, Endoh A, Nakamura R, Adachi K, et al. Hemophagocytic lymphohis- tiocytosis in a rheumatoid arthritis patient treat- ed with infliximab. Intern Med 2012; 51: 655-7. [CrossRef ] Sawar H, Espinoza LR, Gedalia A. Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 623. Araki D, Fujii H, Matsumura M, Yamagishi M, Yachie A, Kawano M. Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med 2011; 50: 1843-8. [CrossRef ] Fardet L, Galicier L, Vignon-Pennamen MD, Regnier S, Noguera ME, de Labarthe A, et al. Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br J Der- matol 2010;162: 547-53. [CrossRef ] Jawed SI, Busam K, Wang X, Horwitz S, Quer- feld C. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sezary syndrome. JAMA Dermatol 2014; 150: 1021-3. [CrossRef ] Lateef A, Tan KB, Lau TC. Acute generalized ex- anthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. Clin Rheumatol 2009; 28: 1449-52. [CrossRef ] Ideguchi H, Ohno S, Takase K, Hattori H, Kirino Y, Takeno M, et al. Successful treatment of re- fractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheuma- tology (Oxford) 2007; 46: 1621-2. [CrossRef ]